Clinical trials: Refractory Neoplasm
Hormone Refractory Prostate Cancer
A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer
This study will review the safety of picoplatin, a new type of platinum drug, with docetaxel, a drug commonly used in the treatment of prostate cancer.
- Trial name
- NCT00448734
- Testing
- Picoplatin, docetaxel
- Where
- 11 sites in Russia
- Volunteers
- 95 people
- Sponsor
- Poniard Pharmaceuticals
Leukemia
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia.
- Trial name
- NCT00002912
- Testing
- etoposide, mitoxantrone hydrochloride, valspodar
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Hormone Refractory Prostate Cancer
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
The goal of this study is to determine the recommended phase 2 dose of the multi-drug combination of abiraterone, cabozantinib, and nivolumab in conjunction with ongoing androgen deprivation therapy in previously untreated…
- Trial name
- NCT04477512
- Testing
- Cabozantinib, Nivolumab, Abiraterone acetate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Advanced / Metastatic Solid Tumor
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint…
- Trial name
- NCT06063681
- Testing
- SR-8541A, Immune checkpoint inhibitor (ICI)
- Where
- 3 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Stingray Therapeutics
Lymphoma
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002481
- Testing
- cisplatin, cyclophosphamide, cytarabine
- Where
- United States
- Sponsor
- St. Luke's Medical Center
Advanced Malignant Neoplasm, Acute Myeloid Leukemia
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies.
- Conditions
- Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia
- Trial name
- NCT04067336
- Testing
- Ziftomenib, Midazolam, Itraconazole
- Where
- 43 sites in United States, Belgium and 5 more
- Volunteers
- 263 people
- Sponsor
- Kura Oncology, Inc.
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies.
- Trial name
- NCT04891744
- Testing
- Selinexor, Thalidomide, Dexamethasone
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Li Zheng
Ovarian Cancer
Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer
The purpose of this study is to determine how effective and safe a new investigational drug is in treating persistent or recurrent ovarian cancer in patients who have received a platinum/taxane based chemotherapy and whose…
- Trial name
- NCT00097409
- Testing
- Ispinesib
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic).
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma
- Trial name
- NCT03670069
- Testing
- Itacitinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
This phase II trial studies how well daratumumab, azacitidine, and dexamethasone work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and was previously…
- Trial name
- NCT04407442
- Testing
- Azacitidine, Daratumumab, Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Francisco
Multiple Myeloma and Plasma Cell Neoplasm
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00017069
- Testing
- arsenic trioxide, dexamethasone
- Where
- 10 sites in United States
- Sponsor
- CTI BioPharma
Lymphoma, Non-Hodgkin, Hodgkin Disease
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with recurrent or refractory Hodgkin or…
- Trial name
- NCT01555853
- Testing
- Abraxane
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Metastatic Pancreatic Cancer
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
To learn if the study drug, YL-13027, is safe to give in combination with gemcitabine and nab-paclitaxel to participants with pancreatic cancer.
- Trial name
- NCT06199466
- Testing
- Gemcitabine, Nab-paclitaxel, YL-13027
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy.
- Conditions
- Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT02048722
- Testing
- regorafenib
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Advanced Cancers, Pain
Cordotomy for Refractory Cancer Pain
The goal of this clinical research study is to learn if a cordotomy reduces pain in patients with unmanageable cancer pain. A cordotomy is a procedure, guided by computed tomography (CT) scans, that is performed on the spinal…
- Trial name
- NCT02345629
- Testing
- Cordotomy, Pain/Symptom Questionnaire, Sharpness Sensory Testing
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Stenosis, Deglutition Disorders
Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis
Management of pharyngoesophageal stenosis (PES) in patients after head and neck cancer (HNC) treatment remains a challenge. There are some cases of strictures refractory to dilation sessions.
- Conditions
- Esophageal Stenosis, Deglutition Disorders, Head and Neck Neoplasms, Esophageal Neoplasms
- Trial name
- NCT03540953
- Testing
- Endoscopic injection of Mitomycin C
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Fauze Maluf Filho
B-cell Acute Lymphoblastic Leukemia
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
This is a study for patients who have been previously treated for B-ALL. The purpose of this study is to determine the safety and feasibility of CART-19 cells to the patients with relapsed and refractory CD19+ B-ALL.
- Trial name
- NCT02924753
- Testing
- Cyclophosphamide, Fludarabine, CART-19 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Multiple Myeloma, Plasma Cell Leukemia
CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia
- Trial name
- NCT05822037
- Testing
- CT0594CP
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Colorectal Cancer
Phase II Trial of RAD001 in Refractory Colorectal Cancer
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
- Trial name
- NCT00337545
- Testing
- RAD001
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Swedish Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.